NURO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NURO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-Revenue measures a company's ability to pay off its debt.
NeuroMetrix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.14 Mil. NeuroMetrix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.00 Mil. NeuroMetrix's annualized Revenue for the quarter that ended in Sep. 2024 was $2.35 Mil. NeuroMetrix's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 0.06.
The historical data trend for NeuroMetrix's Debt-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuroMetrix Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Debt-to-Revenue | Get a 7-Day Free Trial | 0.16 | 0.14 | 0.07 | 0.04 | 0.04 |
NeuroMetrix Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Debt-to-Revenue | Get a 7-Day Free Trial | 0.06 | 0.05 | 0.05 | 0.06 | 0.06 |
For the Medical Devices subindustry, NeuroMetrix's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, NeuroMetrix's Debt-to-Revenue distribution charts can be found below:
* The bar in red indicates where NeuroMetrix's Debt-to-Revenue falls into.
Debt-to-Revenue measures a company's ability to pay off its debt.
NeuroMetrix's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
Debt-to-Revenue | = | Total Debt | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (0.148 | + | 0.092) | / | 5.901 | |
= | 0.04 |
NeuroMetrix's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as
Debt-to-Revenue | = | Total Debt | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (0.143 | + | 0) | / | 2.348 | |
= | 0.06 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.
Thank you for viewing the detailed overview of NeuroMetrix's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Bradley M Fluegel | director | 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204 |
Thomas T Higgins | officer: Chief Financial Officer | |
Topline Capital Management, Llc | other: See Explanation in Footnotes | 544 EUCLID STREET, SANTA MONICA CA 90402 |
Topline Capital Partners, Lp | 10 percent owner | 544 EUCLID STREET, SANTA MONICA CA 90402 |
Mcbirney Collin | other: See Explanation in Footnotes | 544 EUCLID STREET, SANTA MONICA CA 90402 |
Shai Gozani | director, officer: Chairman, President and CEO | C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451 |
Francis X Mcgillin | officer: Senior VP, Consumer | C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451 |
Avermaete David Van | director | C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451 |
Krishnamurthy Balachandran | officer: S. VP and GM, International | C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451 |
Nancy E Katz | director | CALYPTE BIOMEDICAL CORP, 1265 HARBOR BAY PKWY, ALAHEDA CA 94502 |
Neurometrix Inc | officer: Senior Vice President & GM | |
Walter Christensen | officer: Sr. VP, Global Sales | C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451 |
Timothy R Surgenor | director | 100 FOXBOROUGH BOULEVARD, SUITE 240, FOXBOROUGH MA 02035 |
Deerfield Management Company, L.p. (series C) | 10 percent owner | 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010 |
Deerfield Mgmt L.p. | 10 percent owner | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
From GuruFocus
By Marketwired • 05-15-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By Marketwired • 08-13-2024
By Marketwired • 04-19-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.